EPAS1 and neoplasm: New molecular targeted therapies (e.g., tyrosine kinase inhibitors, hypoxia-inducible factor 2 alpha [HIF2α] inhibitors, tumor vaccination, immune checkpoint inhibitors, antiangiogenic therapies, kinase signaling inhibitors) are being evaluated for treating patients with unresectable malignant and metastatic pheochromocytomas [16].